MTWM
INO icon

Masso Torrence Wealth Management’s Inovio Pharmaceuticals INO Stock Holding History

Masso Torrence Wealth Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8
Closed – – 208
2021
Q4 		$0 Buy
+8
New +$641 ﹤0.01% 395

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Masso Torrence Wealth Management's INO Position: Q1 2022 in Review

Masso Torrence Wealth Management sold out of Inovio Pharmaceuticals (INO) in Q1 2022, closing a stake of 8 shares.

Masso Torrence Wealth Management first reported a position in INO in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 198 funds tracked by Wall St. Rank hold INO as of Q1 2022.

  • Masso Torrence Wealth Management reported no remaining Inovio Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Masso Torrence Wealth Management sold 8 Inovio Pharmaceuticals shares in Q1 2022.
  • Masso Torrence Wealth Management first reported a position in Inovio Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Masso Torrence Wealth Management's Inovio Pharmaceuticals position peaked at $0 in Q4 2021.
  • 198 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2022.

Based on Masso Torrence Wealth Management's 13F filing for Q1 2022, filed 26 Apr 2022.